Biographical Sketch

Guy Rutten is professor of Diabetology in Primary Care and Director of the training-course for executives in Diabetology in primary care. His research focuses on type 2 diabetes (T2DM) and cardiovascular complications and diabetes primary care. He is (co-)author of more than 325 original articles in peer reviewed journals and supervised 13 RCTs on T2DM and wrote 10 books on diabetes, guidelines, clinical reasoning and the patient-doctor relationship.

Besides, he worked as a GP from 1982 until 2014 for at least two days/week.

In 2010 he distributed the book ‘Diabetes Care, from Science to Practice’, based on the scientific work of his research group, to all Dutch primary care practices (ZonMW sponsorship). Since 1989 he has been an author of the guidelines on T2DM from the Dutch College of General Practitioners. In 2010 he was nominated for the Dutch Diabetes Research Prize. He was on the writing committee of the global NAVIGATOR study and on the Global Expert Panel of the LEADER trial. From 2006-2008 he was Editor-in-chief of Primary Care Diabetes, from 2005-2011 he chaired the European Primary Care Diabetes Study Group and from 1996 to 2017 the Dutch Diabetes Primary Care Expert Group. He was member of the scientific Advisory Board of the Dutch Diabetes Fund (2004-2010). Currently he is on the Editorial Boards of Lancet Diabetes and Endocrinology and of European Endocrinology.

 

June 2017

 

Interests and Focus

Diabetes and cardiovascular complications Screening on Diabetes Quality of Diabetes Care Insulin in type 2 Diabetes mellitus

Key Publications

• .Insulin monotherapy compared with the addition of oral glucose-lowering agents to insulin for people with type 2 diabetes already on insulin therapy and inadequate glycaemic control.

  13. Vos RC, van Avendonk MJ, Jansen H, Goudswaard AN, van den Donk M, Gorter K, Kerssen A, Rutten GE. Cochrane Database Syst Rev, ., Cochrane Database Syst Rev. 2016 Sep 18;9:CD006992.

• Effectiveness of a self-management intervention in patients with screen-detected type 2 diabetes.

  Thoolen B, De Ridder D, Bensing J, Maas C, Griffin S, Gorter K, Rutten G. Diabetes Care, 2007;30(11):2832-7.

• Increased risk of common infections in patients with type 1 and type 2 diabetes mellitus.

  Muller LM, Gorter KJ, Hak E, Goudzwaard WL, Schellevis FG, Hoepelman AI, Rutten GE. Clinical Infectious Disease, 2005;41(3):281-8.

• Effect of early intensive multifactorial therapy compared with routine care on self-reported health status, general well-being, diabetes-specific quality of life and treatment satisfaction in screen-detected type 2 diabetes mellitus patients (ADDITION-Europe): a cluster-randomised trial

  Van den Donk M, Griffin SJ, Stellato RK, ……, Wareham NJ, Rutten GE. Diabetologia., 2013 Aug 20.

• Effectiveness and cost-effectiveness of 3-monthly versus 6-monthly monitoring of well-controlled type 2 diabetes patients: a pragmatic randomised controlled patient-preference equivalence trial in primary care (EFFIMODI study).

  Wermeling PR, Gorter KJ, Stellato RK, de Wit GA, Beulens JW, Rutten GE. Diabetes Obesity Metabolism., 2014 Sep;16(9):841-9. doi: 10.1111/dom.12288.

• Cognitive function in patients with diabetes mellitus: guidance for daily care.

  Koekkoek PS, Kappelle LJ, van den Berg E, Rutten GE, Biessels GJ. Lancet Neurology., 2015 Mar;14(3):329-40. doi: 10.1016/S1474-4422(14)70249-2.

• Change in quality management in diabetes care groups and outpatient clinics after feedback and tailored support.

  Campmans-Kuijpers MJ, Baan CA, Lemmens LC, Rutten GE. Diabetes Care., 1. 2015 Feb;38(2):285-92. doi: 10.2337/dc14-1860.

• Person-centred type 2 diabetes care: time for a paradigm shift.

  Rutten GEHM, Alzaid A. Lancet Diabetes Endocrinology, 2017

• Screening for type 2 diabetes--where are we now?

  Rutten G. Lancet, 2010 Apr 17;375(9723):1324-6. Epub 2010 Mar 29.

• Effect of valsartan on the incidence of diabetes and cardiovascular events.

  NAVIGATOR Study Group, McMurray JJ, Holman RR, Haffner SM, Bethel MA, Holzhauer B, Hua TA, Belenkov Y, Boolell M, Buse JB, Buckley BM, Chacra AR, Chiang FT, Charbonnel B, Chow CC, Davies MJ, Deedwania P, Diem P, Einhorn D, Fonseca V, Fulcher GR, Gaci New England Journal of Medicine, 2010 Apr 22;362(16):1477-90. Epub 2010 Mar 14.

• Effect of nateglinide on the incidence of diabetes and cardiovascular events.

  NAVIGATOR Study Group, Holman RR, Haffner SM, McMurray JJ, Bethel MA, Holzhauer B, Hua TA, Belenkov Y, Boolell M, Buse JB, Buckley BM, Chacra AR, Chiang FT, Charbonnel B, Chow CC, Davies MJ, Deedwania P, Diem P, Einhorn D, Fonseca V, Fulcher GR, Gaci New England Journal of Medicine, 2010 Apr 22;362(16):1463-76. Epub 2010 Mar 14.

• Effect of early intensive multifactorial therapy on 5-year cardiovascular outcomes in individuals with type 2 diabetes detected by screening (ADDITION-Europe): a cluster-randomised trial

  Griffin SJ, Borch-Johnsen K, Davies MJ, Khunti K, Rutten GEHM et al. Lancet, 2011 Jul 9;378(9786):156-67. doi: 10.1016/S0140-6736(11)60698-3.